Clinical Study on the Safety and Efficacy of Human Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency
Key facts
- Who runs it
- Yan Hongli
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 50 people, planned
- Started
- 15 Oct 2024
- Planned end
- 30 Mar 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Climen 21 Tablets
- hA-MSCs
- Record updated
- 11 August 2025
Who can take part
- Age
- 20 years to 40 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- The intention of pregnant women aged >= 20 and < 40, with normal karyotype
- Oligo/amenorrhea for at least 4 months
- Elevated FSH level >25 IU/l on two occasions >4 weeks apart
- Without a history of stem cell therapy and no growth hormone and/or estrogen and progesterone therapy within the previous 3 months
- Voluntary participation in the study with signed informed consent
Who cannot take part
- Genetic diseases, chromosomal abnormalities, and genetic deficiency that clearly cause premature ovarian insufficiency/premature ovarian failure
- With breast, uterine, ovarian tumors, or any other benign or malignant tumors
- Allergic history to drugs or any other things
- Presence of genetic disorders such as Turner's syndrome, congenital malformations of the reproductive organs
- Have undergone ovariectomy or have organic gynaecological diseases
- Presence of other gynaecological endocrine diseases such as polycystic ovary syndrome
- Severe functional impairment of vital organs
- High risk factors for venous thromboembolism and abnormalities in coagulation mechanisms
- Unable to follow the treatment observation process required by the trial
- Attending doctor considers inappropriate to take part in
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 40 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
There is a high incidence of women suffering from Primary Ovarian Insufficiency (POI). So far, there was no treatment sufficient enough to cure POI. Cell therapy is a rapidly developing field and have shown immense promise in the treatment of ovarian dysfunction. In this study, the investigator will evaluate the safety of human Amniotic mesenchymal stem cells (hA-MSCs) therapy in women suffering from POI.
The 2 groups in the trial
- ClimenExisting treatment, for comparison
Hormone replacement therapy (HRT): Take the drug Climen. Each box has 21 tablets. The first 11 tablets contain 2 milligrams of estradiol valerate each. The last 10 tablets contain 2 milligrams of estradiol valerate and 1 milligram of cyproterone acetate each. Begin taking it on the fifth day of your menstrual cycle. Take one tablet every day for seven days. Then, stop taking the medicine for seven days. After that, continue for two cycles in a row.
Treatment: Climen 21 Tablets
- hA-MSCs+ClimenTreatment being tested
The stem cell treatment group will be administered Climen, with the dosage and method of administration to be determined based on the control group. Concurrently, patients will receive the initial infusion of amniotic MSCs intravenously on the third day after the onset of menstruation, with a subsequent infusion administered after one month. The number of stem cells infused was calculated according to 1 million cells per kilogram of body weight.
Treatment: Climen 21 Tablets and hA-MSCs
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Open-label, Parallel-controlled Clinical Study of Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency
- Criteria questions
- Built from NCT07115082, who can take part
- Record updated
- 11 August 2025